In AML patients, CD123 expression levels are correlated with the number of leukemic stem cells (LSCs) which are CD34+CD38− quiescent cells and demonstrate chemotherapy resistance [82–84]. The gene discussed is CD34; the disease is acute myeloid leukemia.